Here is what needs to happen
Yes, the stock price has been down since 2018.
They have 3 drugs one for inflammation called FSD PEA
One for Major Depressive Disorder which is categorized as a potential treatment for neuropsychiatric disease which uses psychoactive drug that [Lakshmi Kotra](https://www.pharmacy.utoronto.ca/faculty/lakshmi-kotra) and his team discovered it's not patented as of yet.
Lucid MS is patented. LUCID MS for multiple Sclerosis.
They have the facility up for sale, they haven't sold it as of yet hopefully that gets done one day.
Anthony Durkacz is only interim CEO they need to find someone solid with real biotech history to take over in the near future to grow the company even more.
Arbitration has to be dealt with for Raza Bokhari. The courts sided with FSD Pharma against Raza and sent it off to arbitration.
The future of FSD Pharma will be hard to restore unless they get all these things in order. Aside from most biotech Nasdaq indexes being down etc.
So let's see
Zeeshan has been averaging down , so has Anthony Durkacz.
Share Repurchase program is in affect which could reduce the float from 40,5M shares to 38.5M Shares
AD took over as CEO since 2021 July, so the pressure is on him to make sure shareholders are happy and stock price goes up.
The new website looks great.